Invitae Launches Unlock™ Behind the Seizure® Program for Pediatric Epilepsy Patients
Invitae (OTC: NVTAQ) has launched the Unlock™ Behind the Seizure® program, offering accessible and affordable genetic testing for pediatric epilepsy patients under 18. The program aims to shorten the diagnostic process and enable personalized care. Genetic testing is recommended for unexplained epilepsy cases, as over half of epilepsies have genetic causes.
Invitae's epilepsy panel has shown a 1.4-fold higher rate of findings impacting disease management compared to exome tests. In a clinical study, 67% of patients with positive genetic test results experienced reduced or eliminated seizures when treatment was adjusted based on the results. The program also contributes to Invitae's rare disease database, aiding in drug discovery and clinical trial connections.
Invitae (OTC: NVTAQ) ha lanciato il programma Unlock™ Behind the Seizure®, che offre test genetici accessibili e a prezzi contenuti per pazienti pediatrici con epilessia sotto i 18 anni. L'obiettivo del programma è quello di ridurre il tempo di diagnosi e consentire cure personalizzate. I test genetici sono raccomandati per i casi di epilessia inspiegata, poiché oltre la metà delle epilessie ha cause genetiche.
Il pannello di epilessia di Invitae ha mostrato un tasso di riscontri 1.4 volte superiore che influisce sulla gestione della malattia rispetto ai test dell'esoma. In uno studio clinico, il 67% dei pazienti con risultati positivi ai test genetici ha sperimentato una riduzione o l'eliminazione delle crisi quando il trattamento è stato modificato in base ai risultati. Il programma contribuisce anche al database delle malattie rare di Invitae, supportando la scoperta di farmaci e le connessioni con le sperimentazioni cliniche.
Invitae (OTC: NVTAQ) ha lanzado el programa Unlock™ Behind the Seizure®, que ofrece pruebas genéticas accesibles y asequibles para pacientes pediátricos con epilepsia menores de 18 años. El objetivo del programa es acortar el proceso de diagnóstico y permitir una atención personalizada. Se recomiendan pruebas genéticas para casos de epilepsia inexplicada, ya que más de la mitad de las epilepsias tienen causas genéticas.
El panel de epilepsia de Invitae ha mostrado una tasa de hallazgos 1.4 veces mayor que impacta en la gestión de la enfermedad en comparación con las pruebas de exoma. En un estudio clínico, el 67% de los pacientes con resultados positivos en pruebas genéticas experimentaron una reducción o eliminación de las convulsiones cuando se ajustó el tratamiento basado en los resultados. El programa también contribuye a la base de datos de enfermedades raras de Invitae, ayudando en el descubrimiento de medicamentos y conexiones con ensayos clínicos.
Invitae (OTC: NVTAQ)는 Unlock™ Behind the Seizure® 프로그램을 출시하여 18세 미만의 소아 epilepsy 환자를 위한 접근 가능하고 저렴한 유전자 검사를 제공합니다. 이 프로그램의 목표는 진단 과정을 단축하고 개인 맞춤형 치료를 가능하게 하는 것입니다. 유전자 검사는 설명할 수 없는 간질 사례에 권장되며, 간질의 절반 이상이 유전적 원인을 가지고 있습니다.
Invitae의 간질 패널은 엑솜 검사에 비해 질병 관리에 영향을 미치는 결과의 1.4배 높은 비율를 보여주었습니다. 한 임상 연구에서 67%의 환자들이 긍정적인 유전자 검사 결과를 얻은 후, 검사 결과에 따라 치료를 조정했을 때 발작이 감소하거나 제거되었습니다. 이 프로그램은 또한 Invitae의 희귀 질병 데이터베이스에 기여하여 약물 발견과 임상 시험 연결을 도와줍니다.
Invitae (OTC: NVTAQ) a lancé le programme Unlock™ Behind the Seizure®, offrant des tests génétiques accessibles et abordables pour les patients pédiatriques atteints d’épilepsie de moins de 18 ans. L’objectif du programme est de raccourcir le processus de diagnostic et de permettre des soins personnalisés. Les tests génétiques sont recommandés pour les cas d’épilepsie inexpliquée, car plus de la moitié des épilepsies ont des causes génétiques.
Le panel d’épilepsie d’Invitae a montré un taux de découvertes 1,4 fois supérieur influençant la gestion de la maladie par rapport aux tests d’exome. Dans une étude clinique, 67% des patients ayant obtenu des résultats positifs aux tests génétiques ont connu une réduction ou une élimination de leurs crises lorsque le traitement a été ajusté en fonction des résultats. Le programme contribue également à la base de données sur les maladies rares d’Invitae, aidant à la découverte de médicaments et aux liens avec les essais cliniques.
Invitae (OTC: NVTAQ) hat das Programm Unlock™ Behind the Seizure® ins Leben gerufen, das zugängliche und kostengünstige genetische Tests für pädriatische Epilepsie-Patienten unter 18 Jahren anbietet. Das Ziel des Programms ist es, den Diagnosetechnisch zu verkürzen und personalisierte Behandlungen zu ermöglichen. Genetische Tests werden für unerklärte Epilepsiefälle empfohlen, da über die Hälfte der Epilepsien genetische Ursachen hat.
Das Epilepsiepanel von Invitae hat eine 1,4-fache höhere Rate von Ergebnissen gezeigt, die das Krankheitsmanagement im Vergleich zu Exomtests beeinflussen. In einer klinischen Studie haben 67% der Patienten mit positiven genetischen Testergebnissen eine Verringerung oder Beseitigung von Anfällen erfahren, nachdem die Behandlung auf der Grundlage der Ergebnisse angepasst wurde. Das Programm trägt auch zur Datenbank seltener Krankheiten von Invitae bei, um die Arzneimittelforschung und die Verbindung zu klinischen Studien zu unterstützen.
- Launch of Unlock™ Behind the Seizure® program for accessible and affordable genetic testing in pediatric epilepsy
- 1.4-fold higher rate of findings impacting disease management compared to exome tests
- 67% of patients with positive genetic test results experienced reduced or eliminated seizures in a clinical study
- Median turnaround time for test results is 7.5 calendar days, faster than the typical 10-21 days
- None.
Medical Research Analyst: The launch of Invitae's Unlock™ Behind the Seizure® program is a notable advancement in pediatric epilepsy care. It addresses a critical need for accessible and affordable genetic testing, which can significantly reduce the diagnostic journey for young patients. By offering a specialized epilepsy panel, Invitae enhances the likelihood of identifying genetic causes, enabling precision treatment plans. The benefits are twofold: patients receive tailored therapies faster, potentially reducing or eliminating seizures and Invitae strengthens its rare disease database, fostering further research. This initiative aligns with modern clinical guidelines that advocate for early genetic testing in epilepsy, marking a progressive step in pediatric healthcare.
Market Research Analyst: Invitae's strategic introduction of the Unlock™ Behind the Seizure® program has significant implications for the company's market position. By focusing on a highly specialized niche—pediatric epilepsy—Invitae not only addresses a critical healthcare gap but also potentially secures a strong foothold in the rare disease testing market. This move can enhance Invitae's brand reputation as a leader in genetic testing, appealing to both healthcare providers and patients. Additionally, the expansion of their rare disease database through this program can attract biopharma companies interested in precision therapy research, opening up new revenue streams. The initiative is well-timed, leveraging an unmet need to drive growth and innovation.
Financial Analyst: From a financial perspective, the Unlock™ Behind the Seizure® program could be a pivotal growth driver for Invitae. The focus on pediatric epilepsy, a market with urgent, unmet needs, positions Invitae to not only capture market share but also potentially increase revenue through higher testing volumes. The program's success could attract investment from pharmaceutical companies seeking to leverage Invitae's robust rare disease database for drug discovery. However, investors should monitor implementation costs and the program's scalability. If Invitae can manage these effectively, the program may significantly enhance the company's financial health, given the high stakes and high value associated with genetic testing in rare diseases.
– Program provides accessible and affordable testing for pediatric epilepsy patients –
– Genetic and clinical insights from test results to strengthen Invitae's rare disease database –
Millions of people worldwide live with epilepsy and more than half of epilepsies are caused by genetic abnormalities. Clinical practice guidelines recommend genetic testing for all patients with otherwise unexplained epilepsy2, in part because early genetic testing can provide a direct, cost-effective and accurate tool to help support a diagnosis, and is associated with fewer invasive procedures for patients.3
Invitae Unlock Behind the Seizure is designed to make testing for patients under the age of 18 more accessible and affordable by assisting patients. Invitae believes that with results from this program, healthcare providers may gain insights into the underlying genetic cause of their patients' epilepsy, which can inform tailored treatment plans.
In a study, Invitae found that among patients with epilepsy and a molecular diagnosis, those tested with Invitae's epilepsy panel had a 1.4-fold higher rate of findings that impact disease management or prevention, compared to those tested with an exome test.4 Furthermore, healthcare providers reported that genetic diagnosis with this panel changed clinical management for half of the patients tested.5 In fact, in the clinical study by McKnight et al.
In addition to helping patients get a genetic diagnosis and receive the most effective therapy, where therapies for specific conditions don't yet exist, this program helps build the inclusiveness and diversity of Invitae's rare disease database with invaluable genetic and clinical insights from the test results. Biopharma teams harness these insights to inform groundbreaking research in rare disease drug discovery and connect patients to clinical trials and new therapies based on their genetic test results.
"Using genetic testing as a first-line diagnostic, such as through Invitae's Unlock Behind the Seizure, has been shown to dramatically decrease time to diagnosis for children experiencing unprovoked seizures. Earlier genetic diagnosis enables clinicians to provide precision therapies tailored to patients' specific type of epilepsy sooner, reducing or eliminating seizures for many patients with genetic epilepsy, and opening the opportunity to enroll in precision therapy clinical trials for many others." said Dr. Ed Esplin M.D., Ph.D., FACMG, Clinical Geneticist at Invitae. "Invitae is committed to improving outcomes for patients with a multitude of rare diseases. To date, we have provided testing for over 5 million patients, giving answers to patients and their families. With this data set, we are generating one of the largest genomic datasets in service of rare disease treatment research."
Invitae typically returns results within 10-21 days. The recent median turnaround time for this test is 7.5 calendar days, accelerating the time to critical answers for patients and their families who need them most.6 This program is available to individuals in
About Invitae
Invitae (OTC: NVTAQ) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on LinkedIn, X, Instagram, and Facebook @Invitae.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding genetic testing for pediatric epilepsy patients and its Unlock Behind the Seizure program; and the potential results and benefits for the program to strengthen the company's rare disease database, and the ability of biopharma teams to utilize this information. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; risks and uncertainties regarding the company's ability to successfully consummate and complete a plan under chapter 11 or any strategic or financial alternative as well as the company's ability to implement and realize any anticipated benefits associated with its sale of assets to Labcorp and any alternative that may be pursued, including the asset sales and wind down of operations; potential adverse effects of the chapter 11 cases on Invitae's business, financial condition, liquidity and results of operations; employee attrition and Invitae's ability to retain senior management and other key personnel due to the distractions and uncertainties caused by the chapter 11 cases; Invitae's ability to maintain relationships with suppliers, customers, employees, regulatory authorities and other third parties as a result of the chapter 11 cases; the company's public securities' potential liquidity and trading; and any impact resulting from the delisting of the company's common stock from the New York Stock Exchange and trading instead on the OTC Pink Marketplace; and the other risks and uncertainties disclosed in Invitae's annual and quarterly periodic reports and other documents filed with the
Invitae PR Contact
Amy Sands Hadsock
pr@invitae.com
- Truty R, et al. Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open. 2019 Jul 1;4(3):397-408. doi: 10.1002/epi4.12348. PMID: 31440721.
- Smith L, et al. Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors. J Genet Couns. 2023 Apr;32(2):266-280. doi: 10.1002/jgc4.1646. Epub 2022 Oct 24. PMID: 36281494.
- Swartwood SM, et al. Genetic testing for the epilepsies: A systematic review. Epilepsia. 2022 Feb;63(2):375-387. Early Genetic Testing in Pediatric Epilepsy: Diagnostic and Cost Implications. Epilepsia Open. 2023
- Invitae data on file.
- McKnight D et al. Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice. JAMA Neurol. 2022
- Invitae data on file, median TAT of 7.5 during Q2 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-launches-unlock-behind-the-seizure-program-for-pediatric-epilepsy-patients-302201818.html
SOURCE Invitae Corporation
FAQ
What is Invitae's Unlock™ Behind the Seizure® program for NVTAQ stock?
How effective is Invitae's epilepsy panel compared to exome tests for NVTAQ?
What percentage of patients benefited from genetic testing in Invitae's clinical study for NVTAQ?
What is the turnaround time for Invitae's genetic test results for NVTAQ stock?
